Pharmaceutical Technology's Manufacturers' Rankings - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Manufacturers' Rankings
Pharmaceutical Technology&s Annual Manufacturers' Rankings provides perspectives on revenues, product positioning, R&D spending, pharmaceutical manufacturing activity, and capital projects of the major drug companies.


Pharmaceutical Technology


Boehringer Ingelheim. Boehringer Inghelheim (BI) is investing EUR 170 million ($229 million) in its chemical-production facilities in Petersburg, Virginia, and Fornovo, Italy. The company also is doubling capacity for "Respimat" (dabigatran) at its facility in Dortmouth, Germany. The expansion is scheduled to be completed in 2009. In 2006, BI invested EUR 50 million ($68 million) for a new pharmaceutical R&D facility in Biberach, Germany. BI is investing more than EUR 50 million to expand its Cleveland, Ohio, facility. The expansion will include new laboratories and office buildings. In addition, the company is expanding its LogiPack Center packaging facility in Ingelheim, Germany.

Bayer Schering Pharma. Bayer Schering Pharma AG, formed from the Bayer Group's acquisition of Schering AG, is proceeding with an integration plan that will result in annual savings of EUR 700 million ($951 million) from 2009. Bayer announced in 2006 that the integration of the two companies will result in 6100 job cuts.

Schering-Plough. As part of a global manufacturing streamlining effort, Schering-Plough phased out and closed its pharmaceutical manufacturing facility in Manati, Puerto Rico, at the end of 2006 and reduced the workforce in facilities in Las Piedras, Puerto Rico, and Kenilworth, New Jersey. About 1000 employees were eliminated. Also, Schering-Plough invested $38 million in its pharmaceutical-sciences center in Kenilworth and plans to invest an additional $260 million during the next three years.

Reference

1. Holding Pattern: A Special Report on the World's Top 50 Pharma Companies," Pharm. Executive 27 (5), 98–110 (2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here